Connect Biopharma Holdings Ltd., a clinical-stage biopharmaceutical company, has announced the initiation of its Phase 2 Seabreeze STAT Asthma study to evaluate the safety and efficacy of rademikibart for treating acute exacerbations in asthma. This study, which is expected to report topline data in the first half of 2026, aims to establish rademikibart as a potentially groundbreaking biologic treatment for patients experiencing acute asthma exacerbations. Following positive results from a previous global Phase 2 trial, rademikibart has demonstrated the ability to rapidly improve lung function within 24 hours and provide sustained improvements over 24 weeks. The company is also set to begin a similarly-designed Phase 2 study for COPD patients.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。